Cerebraca wafer

DRUG2 trials

Sponsors

Everfront Biotech Co., Ltd.

Conditions

Recurrent GBMRecurrent Glioblastoma, IDH-Wildtype

Phase 1

A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

CompletedNCT03234595

Everfront Biotech Co., Ltd.Recurrent GBM

Start: 2017-11-01End: 2024-09-03Updated: 2024-09-19

Phase 2

Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

Not yet recruitingNCT07349693

Everfront Biotech Co., Ltd.Recurrent Glioblastoma, IDH-Wildtype

Start: 2027-04-01End: 2029-12-31Target: 175Updated: 2026-09-10

Related Papers

Resection and intracranial implant of (Z)- <i>n</i> -butylidenephthalide wafer followed by temozolomide as treatment for recurrent glioblastoma: A randomized phase IIb/III trial.

Journal of Clinical Oncology2026-05-28